Ms TOSHANA FOSTER's Outputs (2)

Mutations in hepatitis C virus p7 reduce both the egress and infectivity of assembled particles via impaired proton channel function (2013)
Journal Article
Bentham, M. J., Foster, T. L., McCormick, C., & Griffin, S. (2013). Mutations in hepatitis C virus p7 reduce both the egress and infectivity of assembled particles via impaired proton channel function. Journal of General Virology, 94, 2236-2248. https://doi.org/10.1099/vir.0.054338-0

Hepatitis C virus (HCV) p7 protein is critical for the efficient production of infectious virions in culture. p7 undergoes genotype-specific protein–protein interactions as well as displaying channel-forming activity, making it unclear whether the ph... Read More about Mutations in hepatitis C virus p7 reduce both the egress and infectivity of assembled particles via impaired proton channel function.

Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release (2013)
Journal Article
Foster, T. L., Thompson, G. S., Kalverda, A. P., Kankanala, J., Bentham, M., Wetherill, L. F., Thompson, J., Barker, A. M., Clarke, D., Noerenberg, M., Pearson, A. R., Rowlands, D. J., Homans, S. W., Harris, M., Foster, R., & Griffin, S. (2014). Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release. Hepatology, 59(2), 408-422. https://doi.org/10.1002/hep.26685

Current interferon‐based therapy for hepatitis C virus (HCV) infection is inadequate, prompting a shift toward combinations of direct‐acting antivirals (DAA) with the first protease‐targeted drugs licensed in 2012. Many compounds are in the pipeline... Read More about Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.